[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE250575T1 - Ep4 rezeptor selektive agonisten zur behandlung der osteoporose - Google Patents

Ep4 rezeptor selektive agonisten zur behandlung der osteoporose

Info

Publication number
ATE250575T1
ATE250575T1 AT00311034T AT00311034T ATE250575T1 AT E250575 T1 ATE250575 T1 AT E250575T1 AT 00311034 T AT00311034 T AT 00311034T AT 00311034 T AT00311034 T AT 00311034T AT E250575 T1 ATE250575 T1 AT E250575T1
Authority
AT
Austria
Prior art keywords
osteoporosis
treatment
selective agonists
receptor selective
receptor
Prior art date
Application number
AT00311034T
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Road
Hauzhu Ke
Bruce Allen Lefker
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE250575T1 publication Critical patent/ATE250575T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00311034T 1999-12-22 2000-12-11 Ep4 rezeptor selektive agonisten zur behandlung der osteoporose ATE250575T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17135399P 1999-12-22 1999-12-22

Publications (1)

Publication Number Publication Date
ATE250575T1 true ATE250575T1 (de) 2003-10-15

Family

ID=22623430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00311034T ATE250575T1 (de) 1999-12-22 2000-12-11 Ep4 rezeptor selektive agonisten zur behandlung der osteoporose

Country Status (36)

Country Link
US (2) US6737437B2 (de)
EP (1) EP1110949B1 (de)
JP (1) JP2001181210A (de)
KR (1) KR100419681B1 (de)
CN (1) CN1413190A (de)
AP (2) AP2002002555A0 (de)
AT (1) ATE250575T1 (de)
AU (2) AU1293101A (de)
BG (1) BG106882A (de)
BR (1) BR0016560A (de)
CA (1) CA2329678A1 (de)
CO (1) CO5251453A1 (de)
CR (1) CR6678A (de)
CZ (1) CZ20022048A3 (de)
DE (1) DE60005471T2 (de)
DK (1) DK1110949T3 (de)
EA (1) EA005293B1 (de)
EE (1) EE200200355A (de)
ES (1) ES2204458T3 (de)
GE (1) GEP20043203B (de)
HR (1) HRP20020537A2 (de)
HU (1) HUP0005001A3 (de)
IL (1) IL140325A0 (de)
IS (1) IS6388A (de)
MA (1) MA26852A1 (de)
MX (1) MXPA02006322A (de)
NO (1) NO20022925D0 (de)
OA (1) OA12117A (de)
PE (1) PE20010953A1 (de)
PL (1) PL356662A1 (de)
PT (1) PT1110949E (de)
SK (1) SK8552002A3 (de)
TR (2) TR200201643T2 (de)
UA (1) UA72293C2 (de)
WO (1) WO2001046140A1 (de)
ZA (1) ZA200007694B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
CN1476429A (zh) 2000-11-27 2004-02-18 �Ʒ� 治疗骨质疏松的ep4受体选择性激动剂
KR100702368B1 (ko) 2001-07-16 2007-04-02 에프. 호프만-라 로슈 아게 프로스타노이드 작용제로서의 2 피롤리돈 유도체
WO2003008377A1 (en) * 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues_as ep4 receptor agonists
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
KR20070087078A (ko) * 2001-07-23 2007-08-27 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하 질환의치료제
CA2467061A1 (en) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Sustained release film preparation for local administration comprising prostaglandin derivative as active ingredient
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
AU2002346561B2 (en) * 2001-12-03 2006-08-17 Merck & Co., Inc. EP4 receptor agonist, compositions and methods thereof
WO2003053923A2 (en) * 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as prostaglandin modulators
CN1653046A (zh) 2002-03-05 2005-08-10 小野药品工业株式会社 8－氮杂前列腺素衍生化合物以及包含该化合物作为活性成分的药物
WO2003077908A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1513589B1 (de) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
CA2483555A1 (en) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
DK2465537T3 (en) 2002-10-10 2016-09-19 Ono Pharmaceutical Co MICROSPHERE INCLUDING ONO-1301
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (de) 2002-11-08 2007-07-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CN1735597A (zh) * 2003-01-10 2006-02-15 霍夫曼-拉罗奇有限公司 作为前列腺素激动剂的2－哌啶酮衍生物
EP1586564B1 (de) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandinderivate und deren medizinische verwendung
ATE394372T1 (de) 2003-03-03 2008-05-15 Serono Lab G-lactamderivate als prostaglandinagonisten
US6734206B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7465755B2 (en) 2003-07-18 2008-12-16 Laboratoires Serono Sa Hydrazide derivatives as prostaglandin receptors modulators
WO2005020917A2 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2537430A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2537410C (en) 2003-09-04 2009-08-11 Merck & Co., Inc. Ophthalmic indazole comprising compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
JP2008507521A (ja) 2004-07-20 2008-03-13 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼科用組成物
ATE455760T1 (de) 2004-12-06 2010-02-15 Merck Serono Sa Pyrrolidin-2-on-derivate zur verwendung als dp1- rezeptoragonisten
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
KR20080000647A (ko) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 경피 흡수 제제
KR100686186B1 (ko) * 2005-06-13 2007-02-26 영진종합건설 주식회사 교량용 배수 구조물
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
JP5262720B2 (ja) 2006-10-26 2013-08-14 小野薬品工業株式会社 貼付剤
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
US8063240B2 (en) 2007-11-14 2011-11-22 Cayman Chemical Company, Incorporated Prostaglandin E1 and E2 analogs for the treatment of various medical conditions
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
KR20140056250A (ko) 2011-08-02 2014-05-09 오노 야꾸힝 고교 가부시키가이샤 좌심실 확장 기능 개선제
CA2879507A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
SG11201507470WA (en) * 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
EP3884935B1 (de) 2013-08-09 2023-06-14 Ardelyx, Inc. Verbindungen und verfahren zur hemmung eines phosphattransports
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (de) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (de) 1981-06-16 1985-09-18 Choay S.A. Arzneimittel als wirksame Substanzverbindungen die den Arylbenzensulfonamid-Typ enthalten und Verfahren zu deren Herstellung
AU6427596A (en) * 1992-04-14 1996-10-31 Alfred Maximillian Stessl A boat hull
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
AU4881697A (en) * 1996-12-20 1998-07-17 Pfizer Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
JP2002527393A (ja) * 1998-10-15 2002-08-27 メルク エンド カムパニー インコーポレーテッド 骨吸収阻害方法
WO2000021542A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
HRP20020537A2 (en) 2004-12-31
AU763983B2 (en) 2003-08-07
GEP20043203B (en) 2004-03-25
EP1110949A1 (de) 2001-06-27
OA12117A (en) 2006-05-04
US20010047105A1 (en) 2001-11-29
DE60005471T2 (de) 2004-04-22
NO20022925L (no) 2002-06-18
EA200200505A1 (ru) 2002-12-26
TR200201643T2 (tr) 2002-11-21
AP2001002357A0 (en) 2001-12-31
WO2001046140A1 (en) 2001-06-28
BG106882A (en) 2003-02-28
IL140325A0 (en) 2002-02-10
ZA200007694B (en) 2002-06-20
HUP0005001A3 (en) 2002-01-28
EP1110949B1 (de) 2003-09-24
NO20022925D0 (no) 2002-06-18
US20020040149A1 (en) 2002-04-04
EA005293B1 (ru) 2004-12-30
IS6388A (is) 2002-05-17
CR6678A (es) 2004-01-14
HUP0005001A2 (hu) 2001-12-28
AU1293101A (en) 2001-07-03
AU7239300A (en) 2001-06-28
US6737437B2 (en) 2004-05-18
JP2001181210A (ja) 2001-07-03
ES2204458T3 (es) 2004-05-01
KR100419681B1 (ko) 2004-02-21
KR20010067415A (ko) 2001-07-12
CZ20022048A3 (cs) 2004-03-17
HU0005001D0 (de) 2001-02-28
PT1110949E (pt) 2003-12-31
SK8552002A3 (en) 2003-09-11
US6642266B2 (en) 2003-11-04
MXPA02006322A (es) 2002-12-13
CN1413190A (zh) 2003-04-23
UA72293C2 (en) 2005-02-15
CO5251453A1 (es) 2003-02-28
MA26852A1 (fr) 2004-12-20
DK1110949T3 (da) 2003-11-24
TR200301841T4 (tr) 2004-01-21
PE20010953A1 (es) 2001-09-25
EE200200355A (et) 2003-10-15
BR0016560A (pt) 2002-09-10
PL356662A1 (en) 2004-06-28
CA2329678A1 (en) 2001-06-22
AP2002002555A0 (en) 2002-06-30
DE60005471D1 (de) 2003-10-30

Similar Documents

Publication Publication Date Title
ATE250575T1 (de) Ep4 rezeptor selektive agonisten zur behandlung der osteoporose
NO20032360D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60138129D1 (de) Apparat zur behandlung von zähnen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE69819515D1 (de) Hydroxy-prostaglandinderivaten zur behandlung der erektilen dysfunktion
ATE370728T1 (de) Antagonisten des gardos-kanals
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
ATE358483T1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DE60012554D1 (de) Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit
DE50009813D1 (de) Kombinationpräparat zur behandlung von sexueller dysfunktion
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
FI5227U1 (fi) Laitteisto laastin jakelemiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1110949

Country of ref document: EP

REN Ceased due to non-payment of the annual fee